Drug Research - Latest News & Updates on Drug Research

Firefly Bio Acquisition Strengthens J&J Cancer Pipeline

Yuvraj — Wed, 10 Jun 2026 12:12:40 +0000

Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Firefly Bio for $1bn in cash, a move aimed at expanding its oncology research portfolio through the addition of Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) technology. The Firefly Bio acquisition is focused on advancing new treatment approaches for solid tumours associated with […]

The post Firefly Bio Acquisition Strengthens J&J Cancer Pipeline first appeared on World Pharma Today.

Sanofi and Owkin Partner to Co-Develop Agentic AI Tools for Drug Discovery

Yuvraj — Tue, 09 Jun 2026 07:54:12 +0000

Sanofi has entered into a multi-year agreement with France-based agentic AI company Owkin to jointly develop next-generation AI-driven biopharma agents. The partnership includes a five-year licence for Owkin’s K Pro platform, an advanced AI system designed to augment drug discovery and development across pharmaceutical workflows. The two companies have maintained a working relationship since 2021, […]

The post Sanofi and Owkin Partner to Co-Develop Agentic AI Tools for Drug Discovery first appeared on World Pharma Today.

Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement

Yuvraj — Mon, 01 Jun 2026 05:50:48 +0000

The Pfizer Innovent Cancer Deal has been finalized, establishing a global licensing and collaboration agreement valued at up to $10.5 billion. The transaction focuses on the research, development, and commercialization of 12 early-stage oncology programs. This arrangement combines the capabilities of both organizations to advance a specialized therapeutic pipeline targeting complex oncology indications. Under the […]

The post Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement first appeared on World Pharma Today.

Transforming the Future of Pharmaceutical Innovation

Yuvraj — Mon, 25 May 2026 07:50:34 +0000

The pharmaceutical industry stands at the edge of a technological revolution, one where quantum computing has the potential to redefine how drugs are discovered, developed, and delivered. As the complexity of diseases grows and the demand for faster, more efficient therapies increases, traditional computational methods are reaching their limits. This is where Quantum.Tech World 2026 […]

The post Transforming the Future of Pharmaceutical Innovation first appeared on World Pharma Today.

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

Yuvraj — Thu, 21 May 2026 07:52:54 +0000

QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing infrastructure and the BioNeMo platform to strengthen AI-driven drug discovery capabilities for pharmaceutical and biotechnology researchers. The collaboration aims to make AI more actionable in research settings by combining advanced bioinformatics tools with curated biomedical knowledge bases. The partnership is designed to help […]

The post QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery first appeared on World Pharma Today.

Bioprocess Analytics Improving Biologics Manufacturing

Yuvraj — Tue, 19 May 2026 13:39:03 +0000

The immense complexity of modern biopharmaceutical production is being navigated through the strategic and systematic application of bioprocess analytics improving biologics manufacturing. By leveraging real-time data streams and advanced monitoring tools, manufacturers can gain a granular, molecular-level understanding of cellular behavior and the surrounding environmental conditions within the bioreactor. This proactive, data-driven approach allows for immediate, automated adjustments that optimize therapeutic yield, ensure absolute product consistency, and significantly streamline the arduous path toward commercial-scale production in a highly regulated global environment.

The post Bioprocess Analytics Improving Biologics Manufacturing first appeared on World Pharma Today.

Cell Therapy Quality Control Improving Clinical Outcomes

Yuvraj — Tue, 19 May 2026 13:37:45 +0000

The long-term success of advanced medicinal products is fundamentally dependent on a rigorous and comprehensive approach to cell therapy quality control improving clinical outcomes. By implementing stringent, multi-stage testing for identity, purity, potency, and safety, manufacturers can guarantee that every individual dose delivered to a patient meets the highest possible standards of GMP compliance. This systematic and data-driven oversight minimizes clinical risks and enhances the reproducibility of complex treatments, ultimately leading to more predictable and successful therapeutic results in the rapidly evolving field of regenerative medicine.

The post Cell Therapy Quality Control Improving Clinical Outcomes first appeared on World Pharma Today.

GMP Cytokines Advancing Cell Therapy Manufacturing

Yuvraj — Tue, 19 May 2026 13:34:19 +0000

The rapid transition of cell-based treatments from the experimental laboratory stage to the standard of clinical care is being enabled by the availability of GMP cytokines advancing cell therapy manufacturing. These vital signaling molecules are absolutely essential for the successful expansion, specific differentiation, and functional activation of therapeutic cell populations, such as CAR T cells used in oncology. By strictly adhering to Good Manufacturing Practice standards, suppliers ensure that these critical raw materials possess the high purity, consistent potency, and clinical safety required for human applications, thereby reducing product variability and significantly enhancing the success rate of regenerative medicine.

The post GMP Cytokines Advancing Cell Therapy Manufacturing first appeared on World Pharma Today.

Recombinant Proteins Driving Biologics Innovation

Yuvraj — Tue, 19 May 2026 13:30:09 +0000

The landscape of modern therapeutic development is being fundamentally reshaped by the precision of recombinant proteins driving biologics innovation. These highly engineered molecules serve as the foundational architecture for initial drug discovery, the creation of sophisticated high-throughput assay development, and the eventual transition into large-scale biologics manufacturing. By utilizing advanced protein expression platforms, the pharmaceutical industry can now produce specific, high-purity proteins that effectively mimic complex natural biological functions with extraordinary accuracy, ensuring that new treatments are both safe and potent for global distribution.

The post Recombinant Proteins Driving Biologics Innovation first appeared on World Pharma Today.

Membrane Proteins Unlocking Drug Discovery Potential

Yuvraj — Tue, 19 May 2026 13:28:07 +0000

A significant majority of the most effective therapeutic targets are located on the cell surface, making the study of membrane proteins unlocking drug discovery potential a top strategic priority for modern pharmaceutical research. These complex and elusive molecules facilitate all critical communication between the cell and its external environment, serving as the primary gateways for hormones, neurotransmitters, and therapeutic drugs. By overcoming the formidable technical hurdles associated with their isolation and molecular stabilization, researchers can now leverage advanced structural analysis and rigorous target validation to design more effective, specific, and safer treatments for a vast array of human diseases.

The post Membrane Proteins Unlocking Drug Discovery Potential first appeared on World Pharma Today.